Compare Stocks: RNA, ACRS, FDMT, and RIGL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.01 -2.4%	$5.65	$1.74 ▼ $6.60	$840.34M	0.78	1.94 million shs	1.22 million shs
FDMT 4D Molecular Therapeutics	$14.67 -1.6%	$12.21	$5.97 ▼ $16.93	$810.43M	2.73	1.04 million shs	1.10 million shs
RIGL Rigel Pharmaceuticals	$46.48 -0.8%	$40.73	$24.95 ▼ $52.24	$859.98M	1.16	347,995 shs	246,113 shs
RNA Avidity Biosciences	$13.64 -2.4%	$12.62	$11.13 ▼ $16.77	$233.32M	N/A	153,667 shs	108,636 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-6.24%	+12.97%	+32.09%	+230.22%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+45.68%	+48.03%	+127.09%
RIGL Rigel Pharmaceuticals	0.00%	+1.29%	+22.12%	+52.44%	+16.99%
RNA Avidity Biosciences	0.00%	+3.33%	+19.02%	+4.92%	-71.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$6.01 -2.4%	$5.65	$1.74 ▼ $6.60	$840.34M	0.78	1.94 million shs	1.22 million shs
FDMT 4D Molecular Therapeutics	$14.67 -1.6%	$12.21	$5.97 ▼ $16.93	$810.43M	2.73	1.04 million shs	1.10 million shs
RIGL Rigel Pharmaceuticals	$46.48 -0.8%	$40.73	$24.95 ▼ $52.24	$859.98M	1.16	347,995 shs	246,113 shs
RNA Avidity Biosciences	$13.64 -2.4%	$12.62	$11.13 ▼ $16.77	$233.32M	N/A	153,667 shs	108,636 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	0.00%	-6.24%	+12.97%	+32.09%	+230.22%
FDMT 4D Molecular Therapeutics	0.00%	-7.33%	+45.68%	+48.03%	+127.09%
RIGL Rigel Pharmaceuticals	0.00%	+1.29%	+22.12%	+52.44%	+16.99%
RNA Avidity Biosciences	0.00%	+3.33%	+19.02%	+4.92%	-71.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$11.50	91.35% Upside
FDMT 4D Molecular Therapeutics	2.80	Moderate Buy	$29.63	101.94% Upside
RIGL Rigel Pharmaceuticals	2.43	Hold	$59.00	26.94% Upside
RNA Avidity Biosciences	2.29	Hold	$63.85	368.08% Upside

Current Analyst Ratings Breakdown

Latest RNA, ACRS, FDMT, and RIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
8/17/2026	FDMT 4D Molecular Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	RIGL Rigel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$40.00 ➝ $49.00
8/17/2026	RIGL Rigel Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2026	RIGL Rigel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00 ➝ $85.00
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/13/2026	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$32.00
8/6/2026	RIGL Rigel Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/6/2026	RIGL Rigel Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$7.83M	107.32	N/A	N/A	$0.85 per share	7.07
FDMT 4D Molecular Therapeutics	$85.21M	9.51	N/A	N/A	$8.85 per share	1.66
RIGL Rigel Pharmaceuticals	$294.28M	2.92	$6.75 per share	6.89	$21.57 per share	2.15
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$64.92M	-$0.58	N/A	N/A	N/A	-921.50%	-61.65%	-42.41%	11/5/2026 (Estimated)
FDMT 4D Molecular Therapeutics	-$140.11M	-$2.63	N/A	N/A	N/A	-194.74%	-41.33%	-35.90%	11/10/2026 (Estimated)
RIGL Rigel Pharmaceuticals	$367.02M	$16.32	2.85	10.76	N/A	116.30%	22.95%	17.19%	11/3/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)

Latest RNA, ACRS, FDMT, and RIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FDMT 4D Molecular Therapeutics	-$1.02	-$1.04	-$0.02	-$1.04	$3.62 million	$3.78 million
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/6/2026	Q2 2026	ACRS Aclaris Therapeutics	-$0.16	-$0.15	+$0.01	-$0.15	$1.38 million	$1.63 million
8/4/2026	Q2 2026	RIGL Rigel Pharmaceuticals	$0.0877	$0.88	+$0.7923	$0.88	$55.28 million	$78.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	3.46	3.46
FDMT 4D Molecular Therapeutics	0.05	8.03	8.03
RIGL Rigel Pharmaceuticals	N/A	1.94	1.79
RNA Avidity Biosciences	N/A	8.73	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
FDMT 4D Molecular Therapeutics	99.27%
RIGL Rigel Pharmaceuticals	66.23%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	4.80%
FDMT 4D Molecular Therapeutics	7.90%
RIGL Rigel Pharmaceuticals	10.47%
RNA Avidity Biosciences	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	139.82 million	133.11 million	Optionable
FDMT 4D Molecular Therapeutics	120	55.24 million	50.88 million	Optionable
RIGL Rigel Pharmaceuticals	160	18.50 million	16.57 million	Optionable
RNA Avidity Biosciences	190	17.11 million	N/A	Optionable

RNA, ACRS, FDMT, and RIGL Headlines

Recent News About These Companies

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages

August 30 at 2:58 AM | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts

August 25, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026 | prnewswire.com

HC Wainwright Has Positive Estimate for RNA Q3 Earnings

August 20, 2026 | americanbankingnews.com

HC Wainwright Issues Optimistic Forecast for RNA Earnings

August 18, 2026 | marketbeat.com

Avidity Biosciences' (RNA) Buy Rating Reaffirmed at HC Wainwright

August 14, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

August 13, 2026 | marketbeat.com

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

August 13, 2026 | prnewswire.com

Q3 Earnings Estimate for RNA Issued By HC Wainwright

August 10, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Now Covered by HC Wainwright

August 6, 2026 | marketbeat.com

Avidity Biosciences (RNA) Expected to Announce Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | prnewswire.com

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026 | prnewswire.com

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

June 14, 2026 | finance.yahoo.com

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

June 12, 2026 | biopharmadive.comB

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

April 23, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 20, 2026 | prnewswire.com

Novartis Uses US Bond Issue To Expand RNA And Peptide Pipeline

March 19, 2026 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RNA, ACRS, FDMT, and RIGL Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$6.01 -0.15 (-2.44%)

As of 08/28/2026 04:00 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

4D Molecular Therapeutics NASDAQ:FDMT

$14.67 -0.24 (-1.61%)

As of 08/28/2026 04:00 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Rigel Pharmaceuticals NASDAQ:RIGL

$46.48 -0.38 (-0.81%)

As of 08/28/2026 04:00 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Avidity Biosciences NASDAQ:RNA

$13.64 -0.34 (-2.43%)

As of 08/28/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, ACRS, FDMT, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, ACRS, FDMT, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, ACRS, FDMT, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, ACRS, FDMT, and RIGL Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

4D Molecular Therapeutics NASDAQ:FDMT

Rigel Pharmaceuticals NASDAQ:RIGL

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RNA, ACRS, FDMT, and RIGL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RNA, ACRS, FDMT, and RIGL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RNA, ACRS, FDMT, and RIGL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RNA, ACRS, FDMT, and RIGL Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

4D Molecular Therapeutics NASDAQ:FDMT

Rigel Pharmaceuticals NASDAQ:RIGL

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools